Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: Mr. Park who wrote (25003)	12/9/1998 5:46:00 PM
From: TokyoMex	Respond to of 119973

RXSD is an IRA stuff .. It has seen the bottom ,,,

To: Mr. Park who wrote (25003)	12/9/1998 5:53:00 PM
From: whyretire	Read Replies (2) \| Respond to of 119973

The ASTM findings sound like a good thing. It could be great, but the findings so far (although promising) are only preliminary -- 10 patients. Further, only 4/10 patients had a successful result. this is not overwhelming. They claim that these patients were sick, and none should have survived, but this is true of all BMT patients. Was there a control group of equally sick patients who received conventional treatment? I don't see one. This may be no better than regular BMT. Why did the others fail? Was it graft vs. host disease? (rejection of the new marrow). How does this compare, again with regular BMT? Hackensack U is not really one of the top 10 in medical research either, but maybe I'm just being snotty. That's the scientific outlook. On the make-a-million outlook, I'm in ASTM and hoping for the best for all of us, especially from Tom B.